Abstract
Paronychia has been described as a side effect in patients undergoing treatment with MEK (mitogen activated protein kinase enzyme) inhibitors. It is usually a recurrent condition that can have a significant impact in the quality of life. Topical beta blocker treatment has been described as an effective therapy in antineoplastic-induced pyogenic granulomas and in antineoplastic-induced paronychia. We describe the first case treated with topical timolol for a trametinib-induced paronychia in a pediatric patient that allowed to continue the third line antineoplastic therapy for his glioma.
Keywords:
induced paronychia; timolol; trametinib.
© 2019 Wiley Periodicals, Inc.
MeSH terms
-
Administration, Topical
-
Adrenergic beta-Antagonists / administration & dosage
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects*
-
Child, Preschool
-
Glioma / drug therapy
-
Humans
-
Male
-
Paronychia / chemically induced
-
Paronychia / drug therapy*
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects
-
Pyridones / administration & dosage
-
Pyridones / adverse effects*
-
Pyrimidinones / administration & dosage
-
Pyrimidinones / adverse effects*
-
Timolol / administration & dosage*
-
Treatment Outcome
Substances
-
Adrenergic beta-Antagonists
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Pyridones
-
Pyrimidinones
-
trametinib
-
Timolol